

DOCKET NO.: CARP-0057



GP 1642 4
4-19-99
#16

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Adir, et al.

Serial No.: 08/846,658

Filing Date: May 1, 1997

For: Humanised Antibodies

APR 19 1999

Group Art Unit: 1642

GROUP 180

Examiner: J. Reeves

DATE OF DEPOSIT:

April 9, 1999

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, DC 20231

Doreen Yatko Trujillo

TYPED NAME: Doreen Yatko Trujillo
REGISTRATION NO.: 35,179

Box NON-FEE
 AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- A Preliminary Amendment.
- An Amendment Responsive to the Office Action Dated November 16, 1998.
- An Amendment Supplemental to the Paper filed _____.
- Other: _____.

04/15/1999 SSALEEKU 00000029 08846658

01 FC:116

380.00 OP

- Small entity status of this application under 37 C.F.R. 1.9 and 1.27 was established in a previous submission.
- A Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.
- Substitute Pages _____ of the Specification are enclosed.
- An Abstract is enclosed.
- _____ Sheets of Proposed Corrected Drawings are enclosed.
- A Certified Copy of each of the following applications: _____ is enclosed.
- An Associate Power of Attorney is enclosed.
- Information Disclosure Statement.
 - Attached Form 1449.
 - A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- Appended Material as follows: _____
- Other Material as follows: _____

FEES CALCULATION

No Additional Fee is Due.

| | | | SMALL ENTITY | | NOT SMALL ENTITY | | |
|---|---------------------------------|---------------------|--------------|--------------|------------------|--------------|--------|
| | REMAINING AFTER AMENDMENT | HIGHEST PAID FOR | EXTRA | RATE | Fee | RATE | Fee |
| TOTAL CLAIMS | 8 | 20 (20 MINIMUM) | 0 | \$9 EACH | \$ | \$18 EACH | \$0 |
| INDEP. CLAIMS | 2 | 3 (3 MINIMUM) | 0 | \$39 EACH | \$ | \$78 EACH | \$0 |
| FIRST PRESENTATION OF MULTIPLE DEPENDENT | | | \$130 | | \$ | \$260 | \$0 |
| <input type="checkbox"/> ONE MONTH EXTENSION OF TIME | | | \$55 | | \$ | \$110 | \$ |
| <input checked="" type="checkbox"/> TWO MONTH EXTENSION OF TIME | | | \$190 | | \$ | \$380 | \$380 |
| <input type="checkbox"/> THREE MONTH EXTENSION OF TIME | | | \$435 | | \$ | \$870 | \$0 |
| <input type="checkbox"/> FOUR MONTH EXTENSION OF TIME | | | \$680 | | \$ | \$1360 | \$0 |
| <input type="checkbox"/> FIVE MONTH EXTENSION OF TIME | | | \$925 | | \$ | \$1850 | \$0 |
| <input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID | | | minus | | (\$) | minus | (\$0) |
| <input type="checkbox"/> TERMINAL DISCLAIMER | | | \$55 | | \$ | \$110 | \$0 |
| <input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS: | | | | | | | 0 |
| TOTAL FEE DUE | | | | | | | \$380 |

A Check is Enclosed in the Foregoing Amount Due.

Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of **November 16, 1998** to and through **April 9, 1999** comprising an extension of the shortened statutory period of **Two (2) month(s)**.

- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.
- The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
 - The Foregoing Amount Due for Filing this Paper.
 - Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
 - Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: *April 9, 1999*

Doreen Yatko Trujillo
Doreen Yatko Trujillo
Registration No. 35,179

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



W
4-19-99
Amndt
17/H

DOCKET NO.: CARP-0057

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Adair et al.

Serial No.: **08/846,658**

Group No.: **1642**

Filed: **May 1, 1997**

Examiner: **J. Reeves**

For: **Humanised Antibodies**

I, Doreen Yatko Trujillo, Registration No. 35,179 certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On April 9, 1999
Doreen Yatko Trujillo
Doreen Yatko Trujillo Reg. No. 35,179

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT AND REQUEST FOR RECONSIDERATION

Pursuant to 37 C.F.R. § 1.115, please amend the above-identified application as a follows.

In the specification:

Page 1, after "September 7, 1994," please insert -- now U.S. Patent No. 5,859,205, --.

Page 1, after "September 17, 1991," please insert -- abandoned, --.

In the claims:

24. (Amended) A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains, which humanized immunoglobulin specifically binds to an antigen with an affinity constant of at least